Consensus PTC Therapeutics, Inc.

Stocks

PTCT

US69366J2006

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-09-22 EDT			5-day change	1st Jan Change
65.96 ^USD	+1.07%		+0.47%	-13.16%

09-15	PTC Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 09:15 AM
08-24	Ptc Therapeutics Announces New Sephience Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as Well as Consistent Favorable Safety Profile	CI

Evolution of the Average Target: PTC Therapeutics, Inc.

Evolution of the Target Price: PTC Therapeutics, Inc.

Changes in Analyst Recommendations: PTC Therapeutics, Inc.

beba43beb555dfae.D4gV21QNR0Y6R1ZZkEFPoLyoqWdWtOJwwpt-II3aQtE.SNt7oRNsFw4NAwkTxCsf-svg5TED2KtCm6MwdL_sLoVtynKXA1suLhcmZg~da9947d57673b7555b676237babc9ef9

Analysts' recommendations: PTC Therapeutics, Inc.

07-27	PTC Therapeutics' Phenylketonuria Physician Survey Yielded Mixed Results on Sephience Launch Momentum, RBC Says	MT
07-07	RBC Capital Adjusts PTC Therapeutics Price Target to $85 From $82, Maintains Sector Perform Rating	MT
06-09	PTC Therapeutics Shares Rise After Upgrade From Citigroup	MT
06-09	Citigroup Upgrades PTC Therapeutics to Buy From Hold, Raise Price Target to $108 From $76	MT
05-08	TD Cowen Upgrades PTC Therapeutics to Buy From Hold, Adjusts Price Target to $90 From $75	MT
04-07	RBC Adjusts Price Target on PTC Therapeutics to $81 From $82, Maintains Sector Perform Rating	MT
02-23	Morgan Stanley Lifts Price Target on PTC Therapeutics to $92 From $90, Keeps Overweight Rating	MT
02-20	RBC Cuts Price Target on PTC Therapeutics to $82 From $87, Keeps Sector Perform Rating	MT
01-08	RBC Lowers Price Target on PTC Therapeutics to $87 From $91, Keeps Sector Perform Rating	MT
12-01	PTC Therapeutics Shares Drop After RBC Downgrade	MT
12-01	RBC Downgrades PTC Therapeutics to Sector Perform From Outperform, Lifts Price Target to $91 From $82	MT
11-05	RBC Capital Adjusts PTC Therapeutics Price Target to $82 From $70, Maintains Outperform Rating	MT
25-10-08	RBC Raises Price Target on PTC Therapeutics to $70 From $63, Keeps Outperform Rating	MT
25-08-08	RBC Raises Price Target on PTC Therapeutics to $63 From $60, Keeps Outperform Rating	MT
25-08-08	Morgan Stanley Raises Price Target on PTC Therapeutics to $76 From $70, Keeps Overweight Rating	MT
25-07-29	UBS Adjusts Price Target on PTC Therapeutics to $80 From $71, Maintains Buy Rating	MT
25-07-29	Truist Raises Price Target on PTC Therapeutics to $86 From $80, Keeps Buy Rating	MT
25-06-04	RBC Raises Price Target on PTC Therapeutics to $60 From $58, Keeps Outperform Rating	MT
25-05-09	BofA Upgrades PTC Therapeutics to Buy From Neutral, Adjusts Price Target to $68 From $55	MT
25-05-07	Citigroup Upgrades PTC Therapeutics to Neutral From Sell, Adjusts Price Target to $40 From $50	MT
25-05-05	RBC Capital Adjusts PTC Therapeutics Price Target to $57 From $65, Maintains Outperform Rating	MT
25-04-03	RBC Lifts Price Target on PTC Therapeutics to $65 From $64, Keeps Outperform Rating	MT
25-02-28	RBC Capital Adjusts PTC Therapeutics Price Target to $64 From $63, Maintains Outperform Rating	MT
25-02-18	RBC Capital Adjusts PTC Therapeutics Price Target to $63 From $60, Maintains Outperform Rating	MT
25-01-07	RBC Cuts Price Target on PTC Therapeutics to $58 From $63, Keeps Outperform Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PTC THERAPEUTICS, INC.					+55.97%
	ELI LILLY AND COMPANY					+13.78%
	JOHNSON & JOHNSON					+3.13%
	ABBVIE INC.					+5.34%
	ROCHE HOLDING AG					+2.89%
	NOVARTIS AG					+7.94%
	ASTRAZENECA PLC					+25.8%
	AMGEN INC.					-1.39%
	NOVO NORDISK A/S					+18.79%
	GILEAD SCIENCES, INC.					+5.04%
	Average					+13.73%
	Weighted average by Cap.					+9.11%